| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1046537146 |
| P356 | DOI | 10.1186/1475-2840-11-32 |
| P932 | PMC publication ID | 3351968 |
| P698 | PubMed publication ID | 22490507 |
| P5875 | ResearchGate publication ID | 223971989 |
| P2093 | author name string | Samir G Mallat | |
| P2860 | cites work | Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. | Q46635542 |
| Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-gro | Q46696295 | ||
| Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy | Q46730814 | ||
| Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults wit | Q46803776 | ||
| Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients | Q46819242 | ||
| Standards of medical care in diabetes--2008. | Q46828447 | ||
| The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). | Q46838076 | ||
| Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension | Q46841118 | ||
| Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies | Q46853613 | ||
| A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring | Q46930417 | ||
| Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens | Q51638920 | ||
| Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. | Q53134419 | ||
| Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials | Q56658918 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes | Q57605349 | ||
| Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials | Q58133760 | ||
| Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy | Q61820502 | ||
| A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension | Q73280063 | ||
| K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 | ||
| Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hy | Q80581209 | ||
| Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk | Q81087587 | ||
| Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control | Q83050024 | ||
| Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema | Q83371577 | ||
| US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 | Q84300422 | ||
| Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients | Q84925519 | ||
| Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis | Q94691477 | ||
| The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) | Q95812285 | ||
| Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 | ||
| Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Q28036762 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. | Q31117595 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study | Q33301894 | ||
| Cardiac and vascular remodelling: effect of antihypertensive agents | Q33541157 | ||
| Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records | Q33659515 | ||
| Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials | Q33803829 | ||
| Renal protection in diabetes: lessons from ONTARGET® | Q34221460 | ||
| Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension | Q34239668 | ||
| Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension | Q34314055 | ||
| Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly | Q34386587 | ||
| The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials | Q34579436 | ||
| Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy | Q34591659 | ||
| Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 | ||
| Fixed-dose combinations improve medication compliance: a meta-analysis. | Q34659858 | ||
| Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study | Q34995916 | ||
| Role of aliskiren in blood pressure control and renoprotection | Q35026735 | ||
| Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease | Q43144865 | ||
| Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial | Q43156210 | ||
| Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension | Q43249315 | ||
| Predictors of hyperkalemia risk following hypertension control with aldosterone blockade | Q43279459 | ||
| Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial | Q43664061 | ||
| Combination therapy in hypertension | Q43702309 | ||
| Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period | Q43762046 | ||
| Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy | Q43785761 | ||
| Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect | Q44090671 | ||
| Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study | Q44274796 | ||
| Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension | Q44474119 | ||
| Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies | Q44538318 | ||
| Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study | Q44985416 | ||
| Sustained antihypertensive activity of telmisartan compared with valsartan | Q45018358 | ||
| A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients | Q45200013 | ||
| The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. | Q45200033 | ||
| Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study | Q45232297 | ||
| Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States | Q45288705 | ||
| Results of treatment with telmisartan-amlodipine in hypertensive patients. | Q45926614 | ||
| Effect of telmisartan on renal outcomes: a randomized trial. | Q46006722 | ||
| Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension | Q46055743 | ||
| Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study | Q46068475 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
| Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome | Q46423266 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. | Q46451243 | ||
| Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers | Q46467059 | ||
| The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study | Q46579672 | ||
| Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy | Q46581957 | ||
| Management of hypertension: summary of NICE guidance | Q46608322 | ||
| Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy | Q46616440 | ||
| Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials | Q35107962 | ||
| Quality of life in the treatment of hypertension. The effect of calcium antagonists | Q35166881 | ||
| Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study | Q35184945 | ||
| Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide | Q35688193 | ||
| Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies | Q35911397 | ||
| Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide | Q35999530 | ||
| Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. | Q36125361 | ||
| Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study | Q36143544 | ||
| Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system | Q36214860 | ||
| Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide | Q36432174 | ||
| Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination | Q36835866 | ||
| Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum | Q37126967 | ||
| Managing hypertension using combination therapy | Q37186577 | ||
| Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients | Q37212350 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system | Q37369848 | ||
| Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy | Q37427232 | ||
| Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide | Q37598918 | ||
| Valsartan: more than a decade of experience | Q37632382 | ||
| Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis | Q37660789 | ||
| Telmisartan: a different angiotensin II receptor blocker protecting a different population? | Q37690442 | ||
| New standards in hypertension and cardiovascular risk management: focus on telmisartan | Q37744529 | ||
| Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement | Q37797817 | ||
| Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals | Q37847949 | ||
| Value of Angiotensin receptor blocker therapy in diabetes | Q37861891 | ||
| Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes | Q37938745 | ||
| Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches | Q37939427 | ||
| Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies | Q38494065 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy | Q42164528 | ||
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
| The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies | Q42594669 | ||
| A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring | Q42635241 | ||
| Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter | Q42676246 | ||
| Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker | Q42683387 | ||
| Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference | Q42842128 | ||
| Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database | Q42920030 | ||
| Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension | Q42976749 | ||
| 24-hour ambulatory blood pressure in the ACCOMPLISH trial | Q42997685 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diabetic nephropathy | Q1129105 |
| mechanism of action | Q3271540 | ||
| arterial hypertension | Q41861 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 32 | |
| P577 | publication date | 2012-04-10 | |
| P1433 | published in | Cardiovascular Diabetology | Q2468083 |
| P1476 | title | What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? | |
| P478 | volume | 11 |
| Q37203105 | A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide |
| Q38113242 | An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors |
| Q41239847 | Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study |
| Q33689466 | Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study |
| Q42939189 | Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo. |
| Q37053287 | Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? |
| Q36373025 | Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure |
| Q37639773 | Efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low-dose combination therapy |
| Q38392298 | Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects |
| Q36448492 | Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the Taichung Diabetes Study |
| Q26824261 | Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension |
| Q36541873 | Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study |
| Q34367671 | Renin-angiotensin system in the kidney: What is new? |
| Q90353253 | Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats |
| Q87226195 | Single-pill combination of telmisartan and hydrochlorothiazide: studies and pooled analyses of earlier hypertension treatment |
| Q28544698 | The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice |
Search more.